Table 1 Treatment of gastric cancer with ZD6126

From: ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer

  

ZD6126 (100 mg kg−1)

 

Control

Weekly

Daily

Body mass (g)±s.e.m.

30.9±0.8

31.3±1.0

29.2±0.7

Tumour volume (mm3)±s.e.m.

440±154

241±39b

79±25a

Tumour mass (g)±s.e.m.

0.5±0.1

0.4±0.1

0.2±0.1b

Incidence of carcinomatosis

10/12 (83.3%)

6/12 (50%)

1/11 (9.1%)c

  1. TMK-1 was injected into the gastric wall on day 0. Therapy with ZD6126, either once a week (weekly) or 5 × per week (daily), was initiated on day 14. Mice were killed on day 38.
  2. aP<0.002 by Student's t-test.
  3. bP<0.05 by Student's t-test.
  4. cP<0.01 by χ2 analysis.
Back to article page